A new compound, discovered jointly by international pharmaceutical company Servier, headquartered in France, and Vernalis (R&D), a company based in the UK, has been shown by researchers at the Walter and Eliza Hall Institute and Servier to block a protein that is essential for the sustained growth of up to a quarter of all cancers.
The research presents a new way to efficiently kill these cancerous cells and holds promise for the treatment of blood cancers such as acute myeloid leukaemia,lymphoma and multiple myeloma, as well as solid cancers such as melanoma and cancers of the lung and breast. It is published online today in the journal Nature.
The Servier compound – S63845 – targets a protein of the BCL2 family, called MCL1, which is essential for the sustained survival of these cancer cells.
Institute scientist Associate Professor Guillaume Lessene, who led the Walter and Eliza Hall Institute’s research team in Melbourne, Australia, said the work provided the first clear preclinical evidence that inhibiting MCL1 was effective in targeting several cancer types.
“MCL1 is important for many cancers because it is a pro-survival protein that allows the cancerous cells to evade the process of programmed cell death that normally removes cancer cells from the body,” Associate Professor Lessene said. “Extensive studies performed in a variety of cancer models have shown that S63845 potently targets cancer cells dependent on MCL1 for their survival.”
The institute team of Associate Professor Lessene worked with haematologist Associate Professor Andrew Wei and Dr Donia Moujalled from The Alfred Hospital and Servier scientists, to demonstrate that not only was S63845 effective against several cancer types, but that it could also be delivered at doses that were well tolerated by normal cells.
Dr Olivier Geneste, Director of Oncology Research at Servier, said this preclinical research represented major findings regarding the druggability of MCL1, a valuable and highly challenging target. “S63845 was discovered through collaboration with the fragment and structure based discovery expertise at Vernalis,” he said. “As part of the ongoing Servier / Novartis collaboration on this target class, clinical development of a MCL1 inhibitor should be launched in the near future.”
Associate Professor Lessene said the research provided further evidence of the usefulness of a new class of anti-cancer drugs called BH3 mimetics. “BH3 mimetics inhibit a group of proteins known as the ‘pro-survival BCL-2 proteins’,” he said. “MCL1 is a member of this protein family, and inhibiting it activates the process of programmed cell death. Walter and Eliza Hall Institute researchers revealed the role of BCL-2 in cancer more than 28 years ago and the essential role of MCL1 for the survival of malignant cells four years ago.”
The Latest on: Cancer treatment
via Google News
The Latest on: Cancer treatment
- Skin Cancer:from types to treatments know allabout skin canceron August 12, 2022 at 5:31 am
Know the different types of skin cancer and what they can do to you and also know about the various treatments that will be helpful ...
- Breast Cancer Patients Now Have New Radiation Treatment Option that Visualizes the Heart and Addresses Co-Morbiditieson August 11, 2022 at 7:58 am
Until now, patients receiving breast cancer radiation treatments have been typically treated using large treatment margins and without the benefit of internal anatomical verification during treatment.
- Traditional Chinese medicine reduces side effect of cancer treatmenton August 11, 2022 at 7:06 am
For tens of thousands of Australians who receive radiotherapy as part of their cancer treatment, mucositis is a serious side effect that may cause inflammation, ulcers, diarrhea, nausea and vomiting, ...
- Research may lead the way to a simpler treatment for canceron August 10, 2022 at 10:29 pm
Sometimes too much of a good thing is not good at all. Inhibiting the function of the PD-1 protein, which blocks immune function, has shown high therapeutic efficacy in cancer immunotherapy.
- Fred Hutch spinout lands $10M for precision test to guide cancer treatment, develop drugson August 10, 2022 at 4:35 pm
Seattle startup SEngine Precision Medicine has raised $10 million to propel drug discovery and development and advance its test that tailors drugs to cancer patients. SEngine cultures patient cancer ...
- Breast cancer: FDA approves Enhertu treatment for HER2-low subtypeon August 10, 2022 at 2:47 pm
The Food and Drug Administration (FDA) approved AstraZeneca’s Enhertu to treat HER2-low breast cancer. Enhertu is the first targeted treatment for this subtype of breast cancer. Following the Enhertu ...
- Cancer treatment not working? Gut bacteria could be cureon August 10, 2022 at 2:37 am
Biomica is in its phase 1 clinical trial for its new cancer drug BMC128, which is expected to help patients who do not respond to immunotherapy.
- Olivia Newton-John has died of breast cancer after it came back for a third time. Here's what you should know about her diagnosis and treatments.on August 8, 2022 at 3:09 pm
Newton-John was first diagnosed with early-stage breast cancer in 1992 when she was 43, and immediately started treatments including chemotherapy.
- Breast Cancer Treatment Effects on Sex Life a Hidden Burdenon August 8, 2022 at 8:03 am
Women with breast cancer commonly see their sexual health decline, yet their doctors aren't telling them what to expect -- or what to do about it.
via Bing News